Since the 1990s, the management of localized or recurrent prostate cancer has been based on risk stratification using clinicopathological variables, including Gleason score, T stage (based on digital rectal examination), and prostate specific antigen (PSA). This evidence concerns the gene KLK3 and prostate cancer.